Agios Pharma (AGIO) Tops Q4 EPS by 12c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Agios Reports Fourth Quarter and Full Year 2019 Financial Results
February 13, 2020 7:00 AM ESTFourth Quarter TIBSOVO® Net Revenue of $19.6M and $59.9M for Full Year 2019; Full Year 2020 U.S. TIBSOVO® Net Revenue Expected to be Between $105-115 Million
New Clinical Data from Mitapivat in Thalassemia and Sickle Cell Disease to be Submitted for Presentation at the European Hematology Association Annual Congress in June
Investigational New Drug Submission for AG-946, a Next Generation PKR Activator, Expected in Q1
CAMBRIDGE, Mass., Feb. 13, 2020 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) today reported business highlights and financial results for the fourth quarter and... More
